Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHRENILIN FORTE vs METHOHEXITAL SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.
Tension-type headache
Induction of anesthesia (FDA-approved),Maintenance of anesthesia (as an adjunct) (FDA-approved),Procedural sedation (off-label),Treatment of refractory status epilepticus (off-label)
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.
Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease.
Terminal elimination half-life is 1.6–4.8 hours (mean ~3.9 hours) in adults. Context: Rapid redistribution shortens clinical duration; elimination half-life is longer in elderly and hepatic impairment.
Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2.
Primarily hepatic metabolism via CYP2B6 and other microsomal enzymes; undergoes oxidation and glucuronidation. Active metabolites are minimally important.
Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally.
Renal: <1% unchanged; hepatic metabolism followed by renal excretion of metabolites accounts for >95% of elimination. Fecal: negligible (<1%).
Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin.
85–90% bound to albumin.
Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg.
2.0–3.0 L/kg; context: High Vd due to extensive tissue distribution, especially to adipose tissue.
Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete).
Intramuscular: ~90–100%; Rectal: ~70–80%; Oral: not available (inactive due to first-pass metabolism).
Not formally established. Acetaminophen component: avoid in severe renal impairment (Cr Cl <10 m L/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for Cr Cl 10-50 m L/min.
No specific dose adjustment required for GFR 30-89 m L/min. For GFR <30 m L/min or dialysis: use with caution; consider reduced dose due to potential prolonged effect.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: use alternative agent or reduce dose by 50% with careful titration.
Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred.
Induction: 1-2 mg/kg IV bolus. Maintenance: 0.5-1 mg/kg IV bolus as needed. Maximum single dose: 100 mg.
Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly.
Reduce initial dose by 25-50% (0.5-1 mg/kg IV) and titrate slowly due to increased sensitivity and prolonged recovery.
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
Risk of respiratory depression and apnea; intravenous administration should be performed only by persons trained in the use of general anesthetics and able to maintain a patent airway and support ventilation. Continuous monitoring of respiratory function is required.
Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment.
Respiratory depression and apnea,Hypotension and bradycardia,Injection site reactions (thrombophlebitis, necrosis, extravasation),Risk of emergence delirium and postoperative confusion,Laryngospasm and bronchospasm,Accumulation with repeated doses in patients with hepatic or renal impairment
Hypersensitivity to any component; porphyria; severe hepatic impairment; concomitant MAO inhibitor use (or within 14 days)
Hypersensitivity to methohexital or other barbiturates,Acute intermittent porphyria or porphyria variegata,Uncontrolled severe hypotension or shock,Status asthmaticus,Severe respiratory insufficiency,Known or suspected massive drug overdose
Avoid alcohol and caffeine-containing foods/drinks (e.g., coffee, tea, cola, chocolate) as they may increase side effects like jitteriness or insomnia. Grapefruit juice may alter caffeine metabolism; consider avoiding. No significant food interactions with acetaminophen or butalbital.
No specific food interactions are documented for methohexital sodium. However, it is recommended to avoid heavy meals immediately before anesthesia to reduce risk of aspiration. Grapefruit juice may theoretically increase barbiturate levels by inhibiting CYP3A4, though clinical significance is unclear. Always follow pre-operative fasting instructions.
First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk.
Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal studies show developmental toxicity at high doses. In the second and third trimesters, there is a risk of fetal depression and neonatal withdrawal if used chronically near term. Avoid in first trimester if possible; use only if clearly needed.
Acetaminophen: minimal excretion, M/P ratio ~0.9, considered compatible. Butalbital: excreted in breast milk, M/P ratio ~0.6, may cause infant drowsiness or withdrawal; caution advised. Caffeine: M/P ratio ~0.5-0.8, generally safe in moderate amounts.
Methohexital enters breast milk in low amounts; the infant dose is estimated at <1% of maternal weight-adjusted dose. M/P ratio is approximately 0.5. Due to potential for neonatal sedation and the drug's short half-life, breastfeeding should be avoided for at least 4-6 hours after maternal administration.
Increased renal clearance and volume of distribution in pregnancy may reduce acetaminophen and caffeine levels; no standard dose adjustment recommended. Butalbital: increased clearance due to hepatic enzyme induction and increased Vd; monitor for reduced efficacy; adjust dose based on clinical response. Avoid supratherapeutic doses.
Pregnancy may alter pharmacokinetics: increased volume of distribution and clearance may require slightly higher initial doses for induction, but no specific dose adjustment is recommended; titrate to effect. Use lowest effective dose due to potential for fetal depression.
Phrenilin Forte is a combination of butalbital, acetaminophen, and caffeine used for tension-type headaches. Butalbital is a barbiturate with high abuse potential; limit to short-term use. Acetaminophen hepatotoxicity risk increases with chronic alcohol use. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of dependence or withdrawal. Avoid in patients with porphyria or severe hepatic impairment.
METHOHEXITAL SODIUM is an ultra-short-acting barbiturate used for induction of general anesthesia. It has a rapid onset (less than 30 seconds) and short duration (5-10 minutes) due to redistribution. It is highly protein-bound and should be used with caution in patients with hypoalbuminemia. Contraindicated in porphyria. Avoid extravasation as it is a tissue irritant. May cause apnea, laryngospasm, and hypotension. Dose reduction needed in elderly or debilitated patients.
Take only as prescribed; do not exceed recommended dose due to risk of liver damage from acetaminophen.,Avoid alcohol while taking this medication to prevent liver toxicity.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Do not use with other products containing acetaminophen to avoid overdose.,If you have a history of substance abuse, inform your doctor; this drug can be habit-forming.,Notify your doctor if you experience signs of liver problems (e.g., yellowing of skin/eyes, dark urine) or symptoms of withdrawal (e.g., anxiety, insomnia, tremors).,Store at room temperature away from moisture and heat.
This medication will cause you to lose consciousness quickly and is only given by a healthcare professional.,You will be closely monitored during and after administration.,You may experience drowsiness, dizziness, or confusion after waking up; do not drive or operate machinery for 24 hours.,Inform your doctor if you have any allergies, porphyria, or liver/kidney disease.,Avoid alcohol and other sedatives for at least 24 hours after receiving this medication.
No interactions on record
"The combination of methohexital, a barbiturate anesthetic, and mesoridazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression and respiratory depression due to synergistic pharmacodynamic effects on GABAergic and dopaminergic pathways. This interaction may result in enhanced sedation, hypotension, and increased risk of respiratory arrest, particularly during induction or maintenance of anesthesia. Patients with underlying respiratory or cardiovascular compromise are at heightened risk for severe adverse outcomes."
"Methohexital, a barbiturate anesthetic, induces cytochrome P450 (CYP) 3A4 enzyme activity, accelerating the hepatic metabolism of azelnidipine, a dihydropyridine calcium channel blocker. This results in reduced plasma concentrations and diminished antihypertensive efficacy of azelnidipine, potentially leading to inadequate blood pressure control during concurrent use."
"Concomitant use of Methohexital, a barbiturate anesthetic with central nervous system (CNS) depressant effects, and Guanfacine, an alpha-2 adrenergic agonist with sedative properties, can lead to additive CNS depression. This may result in enhanced sedation, respiratory depression, hypotension, and bradycardia. Patients may experience excessive drowsiness, impaired cognitive and motor function, and increased risk of falls or respiratory compromise, particularly during anesthesia induction or recovery."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHRENILIN FORTE vs METHOHEXITAL SODIUM, answered by our medical review team.
PHRENILIN FORTE is a Barbiturate Combination Analgesic that works by Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.. METHOHEXITAL SODIUM is a Barbiturate Anesthetic that works by Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHRENILIN FORTE and METHOHEXITAL SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHRENILIN FORTE is: 1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.. The standard adult dose of METHOHEXITAL SODIUM is: Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHRENILIN FORTE and METHOHEXITAL SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHRENILIN FORTE is classified as Category C. First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third tr. METHOHEXITAL SODIUM is classified as Category C. Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.